MedTrace Logo

KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma

NCT03848286 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 153

Last updated 2026-05-05

No results posted yet for this study

Summary

The study is to evaluate the efficacy of KL-A167 injection in subjects with recurrent/metastatic Nasopharyngeal Carcinoma, as measured by Overall Response Rate (ORR) per the Response Evaluation Criteria in Solid Tumors RECIST Version 1.1

Conditions

  • Nasopharyngeal Carcinoma
  • Recurrent or Metastatic

Interventions

DRUG

KL-A167 Injection

KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)

Sponsors & Collaborators

  • Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-06
Primary Completion
2021-07-13
Completion
2022-01-13

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03848286 on ClinicalTrials.gov